Bispecifics expanding the oncology toolkit
T-cell engagers and bispecific antibodies continue to broaden the oncology toolkit across haematological and solid tumours.
Bispecific antibodies are becoming a routine part of how oncologists sequence therapy, particularly in B-cell malignancies. The story to watch is what bispecifics do once they cross from haematology into solid tumours.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- SnapshotAdult diffuse glioma therapy reference (2026)
- ExplainedWhat is glioblastoma?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.